GlassScriptPhysician profile
Anusha Vakiti
NPI 1508229881
$9,717.83
in general payments reported to CMS, 2019-2025
56 companies · $1,752 in 2025
The $1,752 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $289 · 2021: $185 · 2022: $1,577 · 2023: $2,842 · 2024: $3,073 · 2025: $1,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,255 · Education: $211 · Honoraria: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,255.45 |
| Education | $210.80 |
| Honoraria | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $991.14 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $714.24 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $692.29 | 2022-2025 | Lynparza, Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $573.72 | 2022-2025 | |
| Daiichi Sankyo INC. | $550.73 | 2022-2025 | Enhertu, Injectafer |
| Seagen INC. | $485.53 | 2020-2023 | Adcetris, Padcev, Tukysa |
| Amgen INC. | $459.79 | 2020-2023 | Kyprolis, Blincyto, Lumakras |
| Janssen Biotech, INC. | $457.86 | 2022-2025 | Erleada, Darzalex, Akeega |
| Incyte Corporation | $399.01 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $353.62 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Gilead Sciences, INC. | $261.19 | 2023-2025 | Trodelvy |
| Jazz Pharmaceuticals INC. | $236.79 | 2022-2025 | |
| Eisai INC. | $212.19 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $209.71 | 2022-2024 | Fruzaqla, Iclusig, Ninlaro |
| Abbvie INC. | $194.37 | 2022-2024 | Venclexta, Dalvance |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $185.35 | 2022-2024 | Verzenio, Retevmo, Jaypirca |
| Coherus Oncology, INC. | $170.06 | 2022-2025 | Loqtorzi, Udenyca |
| E.R. Squibb & Sons, L.L.C. | $165.36 | 2022-2025 | Opdivo, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $160.72 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $159.67 | 2022-2024 | Onivyde |
| Exelixis INC. | $151.89 | 2023-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $132.23 | 2022-2025 | Ojjaara, Shingrix, Jemperli |
| Alexion Pharmaceuticals, INC. | $125.71 | 2022-2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $125.29 | 2022-2024 | Libtayo |
| Genentech USA, INC. | $117.27 | 2024-2025 | Columvi, Lunsumio, Polivy |
| Puma Biotechnology, INC. | $114.04 | 2022-2024 | Nerlynx |
| Rigel Pharmaceuticals, INC. | $101.33 | 2022-2024 | Tavalisse, Rezlidhia |
| Taiho Oncology, INC. | $95.64 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $95.00 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $89.08 | 2022-2023 | Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.74 | 2023 | Gilotrif |
| Karyopharm Therapeutics INC. | $83.20 | 2022-2024 | Xpovio |
| Array Biopharma INC | $71.79 | 2024-2025 | Mektovi, Lorbrena, Braftovi |
| Stemline Therapeutics INC. | $70.87 | 2022-2024 | Elzonris |
| Beone Medicines USA, INC. | $61.05 | 2025 | Brukinsa |
| Sobi, INC | $58.57 | 2022-2024 | |
| Astellas Pharma US INC | $53.90 | 2022-2023 | Xtandi, Xospata |
| Emd Serono, INC. | $44.45 | 2023-2025 | Tepmetko |
| Acrotech Biopharma INC. | $43.91 | 2023-2025 | Beleodaq |
| Genzyme Corporation | $36.77 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $30.68 | 2022-2023 | Fotivda |
| Geron Corporation | $26.34 | 2025 | Rytelo |
| Genmab U.S., INC. | $25.61 | 2024 | Epkinly |
| Fennec Pharmaceuticals, INC. | $25.00 | 2024 | Pedmark |
| Recordati_rare_diseases_inc. | $23.12 | 2023 | Sylvant |
| Legend Biotech USA INC. | $22.16 | 2025 | Carvykti |
| Renalytix Ai, INC. | $20.12 | 2022 | |
| Pharmaessentia USA Corporation | $20.07 | 2024 | Besremi |
| Pharmacosmos Therapeutics INC. | $19.06 | 2025 | Monoferric |
| Springworks Therapeutics, INC. | $18.34 | 2024 | Ogsiveo |
| Azurity Pharmaceuticals, INC. | $17.88 | 2025 | Danziten |
| Kite Pharma, INC. | $16.97 | 2023 | Yescarta |
| Beigene USA, INC. | $16.49 | 2024 | Brukinsa |
| Servier Pharmaceuticals LLC | $16.31 | 2022 | |
| Foundation Medicine, INC. | $14.33 | 2023 | |
| Adc Therapeutics America, INC. | $14.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anusha Vakiti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.